ReviewCancer science2014
Disease-specific mutations in mature lymphoid neoplasms: recent advances.
Review in Cancer science, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 18 citations in OpenAlex.
- Clonal Hematopoiesis and Solid Cancers.Cancer science · 2025Review
- Melanoma as Subsequent Primary Malignancy in Hematologic Cancer Survivors-A Literature Review.Journal of clinical medicine · 2024Review
- Article
- Ten-eleven translocation-2 affects the fate of cells and has therapeutic potential in digestive tumors.Chronic diseases and translational medicine · 2019Article
- [Revised version of the 4th edition of the WHO classification of malignant lymphomas : What is new?]Der Pathologe · 2019Review
- Clinical and molecular characteristics of unicentric mediastinal Castleman disease.Journal of thoracic disease · 2018Article
- Dysregulation of TET2 in hematologic malignancies.International journal of hematology · 2017Review
- [Classification of malignant lymphomas. Current situation].Der Internist · 2016Review
- Molecular Pathogenesis of Peripheral T Cell Lymphoma.Current hematologic malignancy reports · 2015Review
- Role of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell Neoplasms.Biomarker insights · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mature lymphoid neoplasms (MLN) are clinically and pathologically more complex than precursor lymphoid neoplasms. Until recently, molecular characterization of MLN was mainly based on cytogenetics/fluorescence in situ hybridization, allele copy number, and mRNA expression, approaches that yielded scanty gene mutation information. Use of massive parallel sequencing technologies has changed this outcome, and now many gene mutations have been discovered. Some of these are considerably frequent in, and substantially specific to, distinct MLN subtypes, and occur at single or several hotspots. They include the V600E BRAF mutation in hairy cell leukemia, the L265P MYD88 mutation in Waldenström macroglobulinemia, the G17V RHOA mutation in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, not otherwise specified, and the Y640F//D661Y/V/H/I//N647I STAT3 mutations in T-cell large granular lymphocytic leukemia. Detecting these mutations is highly valuable in diagnosing MLN subtypes. Defining these mutations also sheds light on the molecular pathogenesis of MLN, furthering development of molecular targeting therapies. In this review, we focus on the disease-specific gene mutations in MLN discovered by recent massive sequencing technologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.